| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Substance-K receptor |
|---|
| Ligand | BDBM357792 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | 3H-SB222200 Binding Competition Assay with Human NK-2 Receptor |
|---|
| Ki | >30000±n/a nM |
|---|
| Citation |  Hoveyda, H; Dutheuil, G; Fraser, G N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders US Patent US10214533 Publication Date 2/26/2019 |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Substance-K receptor |
|---|
| Name: | Substance-K receptor |
|---|
| Synonyms: | NK-2 receptor | NK-2R | NK2R | NK2R_HUMAN | NKNAR | Neurokinin 2 receptor | Neurokinin A receptor | Neurokinin NK2 | Neurokinin-2 (NK-2) | Neuromedin-2 receptor (NK-2R) | SKR | TAC2R | TACR2 | Tachykinin receptor 2 | Tachykinin receptor 2 (NK2) | hnk-3 |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 44455.78 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P21452 |
|---|
| Residue: | 398 |
|---|
| Sequence: | MGTCDIVTEANISSGPESNTTGITAFSMPSWQLALWATAYLALVLVAVTGNAIVIWIILA
HRRMRTVTNYFIVNLALADLCMAAFNAAFNFVYASHNIWYFGRAFCYFQNLFPITAMFVS
IYSMTAIAADRYMAIVHPFQPRLSAPSTKAVIAGIWLVALALASPQCFYSTVTMDQGATK
CVVAWPEDSGGKTLLLYHLVVIALIYFLPLAVMFVAYSVIGLTLWRRAVPGHQAHGANLR
HLQAMKKFVKTMVLVVLTFAICWLPYHLYFILGSFQEDIYCHKFIQQVYLALFWLAMSST
MYNPIIYCCLNHRFRSGFRLAFRCCPWVTPTKEDKLELTPTTSLSTRVNRCHTKETLFMA
GDTAPSEATSGEAGRPQDGSGLWFGYGLLAPTKTHVEI
|
|
|
|---|
| BDBM357792 |
|---|
| n/a |
|---|
| Name | BDBM357792 |
|---|
| Synonyms: | (4-chlorophenyl)(3-(3- methyl-1,2,4-thiadiazol-5- yl)-5,6-dihydro- [1,2,4]triazolo[4,3- a]pyrazin-7(8H)- yl)methanone | US10214533, Compound 2 | US9969738, 2 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C15H13ClN6OS |
|---|
| Mol. Mass. | 360.821 |
|---|
| SMILES | Cc1nsc(n1)-c1nnc2CN(CCn12)C(=O)c1ccc(Cl)cc1 |
|---|
| Structure | 
|
|---|
Search and Browse
